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Liver fibrosis is a wound-healing response to chronic liver injury characterized by progressive inflammation and deposition
of extracellular matrix components. The pathological condition of liver fibrosis involves secretion of extracellular matrix
proteins and formation of scar tissue. The major regulators involved in hepatic fibrogenesis are the transforming growth
factor (TGF)-β1/SMAD and toll-like receptor 4 (TLR4)-initiated myeloid differentiation primary response 88 gene
(MyD88)/NF-ĸB cell signaling pathways. This article reviews natural products and herbal medicines that have
demonstrated activity against liver fibrosis through different mechanisms of action, including anti-hepatitis B and
C virus activity, anti-inflammation, inhibition of cytokine production and nuclear receptor activation, and free
radical scavenging.Introduction
Chronic liver injury increases extracellular matrix (ECM)
deposition by activating the hepatic stellate cells (HSCs).
This results in liver fibrosis, which is a major cause of mor-
tality worldwide mainly because of chronic infection with
the hepatitis virus and obesity associated with fatty liver dis-
ease [1]. Cirrhosis occurs in the final stage of liver fibrosis
and is characterized by the distortion of liver vasculature
and architecture that increases the likelihood of liver failure
and primary liver cancer [2]. At present, there are no medi-
cations to manage liver fibrosis; the only treatment is tissue
transplantation. The range of biological activities offered by
natural products and herbal medicines has increased inter-
est in their potential for treating liver fibrosis.
We review natural products and herbal medicines that
have demonstrated activity against liver fibrosis through
different mechanisms of action, including anti-hepatitis B
and C virus activity, anti-inflammation, inhibition of cyto-
kine production and nuclear receptor activation, and free
radical scavenging. PubMed and Google Scholar were
searched for references before the end of 2014 using the
following combination of keywords: liver fibrosis and nat-
ural product; liver fibrosis and herbal medicine; liver fibro-
sis and Chinese medicine; liver fibrosis and Clinical trials;
liver fibrosis and mechanism of action.* Correspondence: emilyywang@umac.mo; ytwang@umac.mo
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Pathogenesis of liver fibrosis
Liver fibrosis is a wound-healing response to chronic
liver injury involving accumulated inflammation, which
leads to the increased deposition of ECM and scar tissue
[3]. It progresses at different rates in patients with vari-
ous types of chronic liver injury [3]. Principal collagen-
producing cells in the fibrotic liver include activated
HSCs, portal fibroblasts, and myofibroblasts of bone
marrow origin [4,5]. Among them, activated myofibro-
blasts are most responsible for forming fibrotic tissue as-
sociated with most chronic liver diseases [6]. The precise
origin of activated myofibroblasts is unknown, but several
types of cell may be implicated. Bone marrow-derived
fibrocytes, or circulating mesenchyme cells, migrate
through the injured liver and differentiate into myofibro-
blasts during fibrogenesis [7]. In addition, hepatocytes, si-
nusoidal endothelial cells, Kupffer cells, and lymphocytes
may contribute to liver fibrosis [7].
Under normal conditions, HSCs store retinoid and re-
main in a quiescent state, with expression of adipocyte
markers, including peroxisome proliferation-activated
receptor-γ (PPAR-γ), sterol regulatory element binding
protein-1c, and leptin [8]. HSCs are activated to pro-
duce different types of ECM proteins in conditions of
chronic inflammation [9]. Activated HSCs are characterized
by myogenic markers like α-smooth muscle actin (α-SMA),
c-Myb, and myocyte enhancer factor-2 [10].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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TGF-β1 is a member of the TGF β superfamily [11] and is
involved in liver fibrosis (Figure 1A). Under normal condi-
tions, TGF-β1 binds to latency-associated peptide and re-
mains inactivated. Upon activation, TGF-β1 binds to its
receptors and phosphorylates the downstream signalFigure 1 Signaling pathway mediates hepatic fibrogenesis: (A) the TGF-β1/SMASMAD2/3. Phosphorylated SMAD2/3 recruits the com-
mon mediator SMAD4 to form a hetero-oligomer com-
plex. The SMAD complex then translocates into the
nucleus and activates transcription of collagens [12]. Ele-
vated collagen expression induces trans-differentiation of
myofibroblasts, which secrete ECMS that can overwhelmD signaling pathway, and (B) TLR4 activated-MyD88/TGFβ1/NFκB pathway.
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brosis [13].
Sustained signaling from the TGF-β1 cascade prolifer-
ates HSCs, which also produce ECMs, resulting in fibrous
scars [4]. TGF-β1 stimulates myofibroblast differentiation
through the phosphatidylinositol 3-kinase (PI3K)-Akt
pathway. Upon liver damage, TGF-β1 activates Akt signal-
ing via p38 mitogen-activated protein kinase and focal ad-
hesion kinase (FAK). Prolonged activation of the above
cell signaling pathways ultimately leads to inflammatory
conditions in the liver, resulting in liver fibrosis [14].TLR4 promotes liver fibrosis through transcription of
inflammation cytokines
Almost all hepatic cells with elevated levels of TLR4 are
related to fibrotic progression (Figure 1B) and promote
liver fibrosis [15]. TLR4 induces transcription of genes re-
lated to fibrogenesis through the MyD88/NFκB cascade
[16]. Upon damage, lipopolysaccharide (LPS) interacts
with circulating LPS-binding protein and binds to
TLR4 through the co-receptors cluster of differenti-
ation 14 (CD14) and lymphocyte antigen 96 [17]. The
LPS/TLR4 complex then activates downstream path-
ways via the bridging adaptor TIR-domain-containing
adaptor protein (TRIAP) dependent on MyD88 or the
TIR-domain-containing adapter-inducing interferon-β
(TRIF).
In a MyD88-dependent manner, MyD88 recruits IRAK4
(IL-1 receptor associated-kinase-4) through an interaction
between their death domains. Once activated, IRAK4
triggers further activation of IRAK1 and IRAK2. The
activated IRAKs then dissociate from the MyD88
complex and interact with tumor necrosis factor
receptor-associated factor-6 (TRAF6). The IRAKs/
TRAF6 complex binds to TAK1 (TGF-β activated kin-
ase 1), which subsequently leads to phosphorylation
and ubiquitination of subunits of the IκB kinase com-
plex. Then NF-κB will be released from the IκB kinase
complex and translocate into the nucleus after IκBα
phosphorylated and ubiquitinated [18], inducing tran-
scription of inflammatory cytokines related to liver
fibrogenesis, including interleukin 6 (IL-6), IL-12, and
tumor necrosis factor α (TNFα) [19].
In the TRIF-dependent signaling pathway, LPS activates
the receptors and recruits the adaptor TRIF. Subsequently,
TRIF activates TANK-binding kinase 1 (TBK1) and
receptor-interacting protein 1 (RIP1). The TRIF/TBK1
signaling complex then phosphorylates interferon
(IFN) regulatory factor 3 (IRF3). The phosphorylated
IRF3 translocates into the nucleus and activates tran-
scription of type I IFN. The activated RIP1 also trig-
gers polyubiquitination and activation of TAK1 and
NF-κB.Bile acid homeostasis and xenobiotic detoxification
receptors
Nuclear receptors and cell surface receptors regulate the
initiation and progress of liver fibrosis [20]. Bile acid reg-
ulates hepatic lipid metabolism through binding to its
nuclear receptor farnesoid X receptor (FXR) [21]. Bile
acid-activated FXR induces transcription of repressor
small heterodimer partner mRNA (SHP). SHP then
binds to liver receptor homolog-1 and inhibits the ex-
pression of cholesterol 7α-hydroxylase (CYP7A1, or cyto-
chrome P4507A1). Decreased CYP7A1 expression
suppresses the multiple-step conversion of cholesterol to
primary bile acid (or cholic acid) and thus attenuates the
progression of liver fibrogenesis [22]. SHP also binds to
retinoid X receptor α (RXRα) and retinoic acid receptor
(RAR), which represses synthesis of the hepatic bile salt
and thus reduces one of the contributing factors of liver
fibrosis [23]. The activated FXR bound to SHP also pro-
motes quiescence and apoptosis of activated HSCs in
the fibrotic liver [24].
Bile acid also activates vitamin D receptor (VDR), a
member of the nuclear hormone receptor superfamily
[25]. Together with FXR, VDR regulates bile acid
homeostasis and xenobiotic detoxification in the liver.
VDR ligands prevent liver fibrosis by deactivation of
HSCs through downregulation of the TGF-β1/SMAD
pathway [25].Other cell signaling pathways involved in liver fibrosis
The FAK PI3K-Akt signaling pathway plays a major role
in the activation of HSCs [26]. The PI3K complex con-
sists of a p110 catalytic subunit and a p85 regulatory
subunit. The activated PI3K catalyzes the reaction to
produce Ptdlns(3,4,5)P3 and Ptdlns(3,4)P2, which bind
to the pleckstrin homology domain of Akt and trigger its
plasma membrane translocation and activation. Fully ac-
tivated Akt promotes proliferation and survival in HSCs
and other cell types [27].
The PPAR pathway is closely related to the activation
of HSCs in liver fibrosis [28]. PPAR-γ, a key regulator of
connective tissue homeostasis, inhibits fibrogenesis in
HSCs and attenuates liver fibrosis in vivo [28]. The
expression of PPAR-γ is mainly regulated by the TGF-
β1/SMAD signaling pathway [29]. Other transcription
factors like nuclear factor-like 2 (Nrf2) and cytokines
(TNF-α, IL-6, IL-13) can also activate HSCs and pro-
mote liver fibrosis [30].Free radicals induce liver damage
Reactive oxygen species (ROS) are related to chronic
liver damage and fibrogenesis [31]. ROS stimulate ex-
pression of cytokines, hormones, and growth factors and
ROS-generated cytokines like platelet-derived growth
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fibrogenesis [32].
The balance of EMT and MET governs hepatic
fibrogenesis
Epithelial-mesenchymal transition (EMT) is the process
by which epithelial cells lose apicobasal polarity and
intercellular adhesion complexes change phenotypes
dramatically and move through the ECM like mesenchy-
mal cells [33]. The balance between EMT and its reverse
process, mesenchymal-to-epithelial transition (MET),
determines the progression of liver fibrosis [33]. EMT is
usually triggered by the growth factors-induced expres-
sion of Snail and TM4SF5 [34]. The activated HSCs in
the fibrotic liver also undergo an EMT as revealed by el-
evated mesenchymal and epithelial markers [35]. Other
regulators, such as cadherins, microRNAs, transcription
factors (e.g., Pax, paraxis, and Fox) and growth factors
(e.g., Wnts, FGFs, and ephrins) are also involved in
maintaining the balance of EMT and MET [36,37].
Commonly used liver fibrosis animal models
Laboratory animal models are based on the above patho-
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Standard transgenic methodThe most commonly used laboratory liver injury model
is induced by chemical reagents like carbon tetrachloride
(CCl4) or alcohol. Transgenic animal models manipulate
the expression of key signaling molecules like TGF-β1 to
mimic the pathological condition of liver fibrosis. We
summarize the most commonly used animal models in
Table 1.
Potent natural products and herbal medicines for
the management of liver fibrosis
From Table 2, we can see that there are a lot of potent
natural products and herbal medicines for the manage-
ment of liver fibrosis. But effective therapeutic options
are limited in liver fibrosis [38]. Because of its diverse
pathogenetic mechanisms, its management may include
antiviral or anti-inflammatory approaches, inhibition of
cytokine production, modulation of nuclear receptors,
reduction of cellular oxidative stress, and EMT and
MET balance.
Antiviral drugs attenuate chronic hepatitis infection
Chronic hepatitis B and C virus (HBV and HCV) infec-
tion is the leading cause of liver fibrosis. Nucleoside/nu-
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significance, but expensive, and early
death with limited application
[120]
Hepatic lesions resembling primary
sclerosing cholangitis, convenient but
expensive
[121]
Table 2 Pharmacological effects of natural products and herbal medicines with anti-liver fibrosis activity
Natural product/
herbal medicine
Pharmacological effect Model system References
Helioxanthin Inhibited HBV replication, suppressed IL-1-induced
c-jun transcription and c-jun-mediated DNA binding activity of AP-1
HBV-producing HepG 2.2.15 cell line [44]
Wogonin Suppressed secretion of HBV antigens and reduced HBV DNA level
through inhibition of HBV DNA polymerase activity
HBV-producing MS-G2 cell line [46,47]
Matrine and
oxymatrine
Inhibited HBV surface antigen secretion, E antigen, and HBV DNA
replication
HBV-producing HepG 2.2.15 cell line [48,49]
Rhodiola kirilowii
Maxim
Inhibited HCV NS3 serine protease activity Cos-7(NS3/4A-SEAP) cell line [50]
Green tea Inhibited HCV viral entry and replication Primary human hepatocyte cells
infected with HCV pseudoparticles,
HCV-JFH1 viral culture system, patients
with HCV infection and detectable
viremia
[51-53]
Glycyrrhizin acid Inhibited HCV full-length viral particle and HCV core gene expres-
sion syngenetically with IFNα, reduced hepatic inflammation, pre-
vented apoptosis and inflammatory infiltrates
HCV-infected liver cells, BALB/c mice [54-56]
Nobiletin Inhibited HCV absorption, reduced hepatic inflammation Human lymphoblastoid leukemia
MOLT-4 cell line, and primary cultured
rat hepatocytes
[57,58]
Genistein Decreased levels of inflammation mediators, including IL-6, TNFα,
and myeloperoxidase
CCl4-induced rat hepatic fibrosis [61]
Salvianic acid A Inhibited proliferation of HSCs, reduced expression of TGF-β1 and
collagen I/III
HSC-T6 cell line [62]
Betulin, betulinic
acid
Inhibited expression of TNFα, TGF-β1, TIMP-1, TIMP-2, and MMP-2 Alcohol-induced liver fibrosis [63,64]
Gexia Zhuyu Tang Attenuated fibrogenesis and reduced inflammation, reduced CCl4-
induced collagen deposition
Late-stage liver fibrosis patients, CC4-
induced mouse liver fibrosis
[65,66]





De-repressed PPAR-γ through suppression of canonical Wnt signal-
ing in activated HSCs





Decreased serum IFN-γ and IL-12 levels, inhibited α-SMA activation
and transcription of its target genes
Rat liver fibrosis model [75,76]
Paeoniflorin Reduced the size of egg granuloma, fibrosis scores, serum IL-13
levels, and hydroxyproline content, and blocked IL-13 signaling
pathway
CCl4-induced rat hepatic fibrosis [77,78]
Oleanolic acid,
ursolic acid
Inhibited bile acid production by blocking the interaction between FXR
and its coactivator SRC-3 and endogenous ligand chenodeoxycholic
acid, suppressed expression of FXR-targeted bile salt export protein,
reduced hepatic free radicals through increasing hepatic transcription
of Nrf2 target genes
HepG2 cell line, wild-type and Nrf2-null
mice
[80-82]
Silymarin Protected liver from further damage through antioxidant and anti-
inflammatory activity
CCl4-induced rat liver fibrosis [84,85]




Reduced lipid peroxidation and oxidative stress CCl4-induced mouse liver fibrosis [87,88]
Curcumin Suppressed multiple proangiogenic factors that modulate
cannabinoid receptors, inhibited ECM expression, decreased
collagen deposition, increased serum MMP-13 and glutathione
levels
CCl4-induced rat liver fibrosis [89-91]
β-caryophyllene Exhibited high scavenging activity against hydroxyl radicals and
superoxide anions, inhibited lipid peroxidation, suppressed
expression of Col1a1 and TIMP-1
CCl4-induced mouse liver fibrosis [93]
Diwu Yanggan
formula
Modulated the EMT and MET balance CCl4-induced rat liver fibrosis [94]
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Table 2 Pharmacological effects of natural products and herbal medicines with anti-liver fibrosis activity (Continued)
Salvianolic acid B Abrogated EMT-induced fibrogenesis Renal fibrosis model [96]
Fuzheng Huayu
tablet
Reversed EMT in the fibrotic kidney through suppression of α-SMA,
TGF-β1, and nuclear translocation of SMAD3; induced apoptosis
through p38 and SAPK/JNK pathways; decreased transcription of
TIMP-1, PDGF-B, and PDGF receptor β1; reversed HBV-induced fibrosis
and cirrhosis; prevented TGF-β1-induced EMT
Renal fibrosis model, HSC-T6 cells, pa-
tients with chronic hepatitis B, patients










Reduced liver fibrosis scores and downregulated fibrosis markers,




Obeticholic acid Inhibited synthesis and accumulation of bile acid in the liver,
reduced liver inflammation and fibrosis
Patients with type 2 diabetes and non-




Suppressed Procol1α1 and TGF-β1, inhibited hepatic inflammation
and oxidative stress markers, including TLR4, TLR9, CD14, MyD88,
and NADPH oxidase subunits
Western diet-induced NASH in Ldlr(−/−)
mice
[114]
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ribavirin and direct acting antivirals are used to treat
HCV patients [42]. Long-term use of most virus-
targeted antiviral therapies may cause drug resistance
and side effects, so agents to illuminate drug resistance
are needed.
Helioxanthin (Figure 2) was originally isolated from the
shrub Taiwania cryptomerioides (Taiwan Shan). Heliox-
anthin exhibited potent inhibitory activity against HBV
replication in HepG 2.2.15 cells and Lamivudine-resistant
HBV L536M/M550V double mutant HBV strain [43].
Treatment with helioxanthin suppressed IL-1-induced
c-jun transcription and c-jun-mediated DNA-binding
activity of AP-1 [44]. In one study, a synthesized derivative
of helioxanthin, 8–1, suppressed HBV replication by de-
creasing the binding of hepatocyte nuclear factors 3 and 4
to the HBV replication machinery [45].ECG EGCG 
Helioxanthin Wogonin M
Figure 2 Natural products that inhibit HBV, and HCV replication.The herbal medicine Scutellaria baicalensis (Huangqin)
has been used to reduce inflammation [46]. Wogonin
(Figure 2) isolated from Scutellaria baicalensis exhib-
ited potent anti-HBV activity both in vitro and in vivo.
Treatment with wogonin suppressed secretion of HBV
antigens and reduced HBV DNA levels through inhi-
bition of HBV DNA polymerase activity in the HBV-
producing MS-G2 cell line [47].
Matrine and oxymatrine (Figure 2), two alkaloids iso-
lated from the root of the plant Sophora japonica
(Kushen), reversed liver fibrosis through downregulation
of the TGF-β1 pathway [48]. A combination treatment
of matrine or oxymatrine with Lamivudine reduced
chronic HBV infection-induced liver fibrosis through
inhibiting secretion of hepatitis B surface antigen
(HBsAg) and hepatitis B e antigen (HBeAg), and replica-
tion of HBV DNA [49].Nobiletin Glycyrrhizin acid 
atrine  Oxymatrine 
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and (−)-epicatechin-3-O-gallate (ECG) (Figure 2), from
the herbal medicine Rhodiola kirilowii (Regel) Maxim
(Xiaye Hongjingtian) exhibited potent inhibitory effect
against HCV NS3 serine protease with low cytotoxicity
[50]. Polyphenols extracted from green tea also exhibited
potent activity against HCV viral entry [51] and replica-
tion [52]. In one study, a single oral administration of
green tea extract containing 94% pure EGCG was safe
and well-tolerated by all 11 patients with cirrhosis asso-
ciated with chronic HCV infection [53].
Glycyrrhizin acid (Figure 2), the major component of
the root of Glycyrrhiza glabra (Yanggancao), inhibited
expression of the HCV full-length viral particle and
HCV core gene synergistically with IFNα [54]. Treat-
ment with glycyrrhizin acid reduced hepatic inflamma-
tion through regulation of CD4+ T cell response in a
JNK-, ERK-, and PI3K-Akt-dependent manner in mice
with liver injury [55]. Glycyrrhizin acid prevented apop-
tosis and inflammatory infiltrates induced by LPS/GaIN
injection through disturbing the binding of HMGB1 pro-
tein to the promoter of Gsto1 [56].
Nobiletin (3′,4′,5,6,7,8-hexamethoxyflavone, Figure 2),
the active component of Citrus unshiu peel, markedly
inhibited HCV absorption in the human lymphoblastic
leukemia MOLT-4 cell line [57] and reduced hepatic in-
flammation through reducing iNOS and DNA-binding
activity of nucleus NF-κB [58].Genistein  
Betulin  
Figure 3 Chemical structures of natural products with anti-inflammation aAnti-inflammatory drugs reduce liver inflammation
Anti-inflammatory drugs, including corticosteroid, pred-
nisone, and prednisolone, suppress cytokine transcrip-
tion, thus inhibiting hepatic collagen deposition [59].
These drugs can only effectively and safely treat liver fi-
brosis in combination with azathioprine [59].
Genistein (Figure 3) is a type of isoflavone first isolated
from Hydrocotyle sibthorpioides (Tianhusui) and consid-
ered a potent chemopreventive agent with estrogenic ac-
tivities against breast cancer [60]. Treatment with
genistein decreased levels of inflammation mediators, in-
cluding IL-6, TNF-α, and myeloperoxidase, through
downregulation of NF-κB in alcohol- and CCl4-induced
liver fibrosis in rats [61].
Salvianic acid A (Figure 3), one of the most widely
used natural products in China, is the main active com-
ponent of Salvia miltiorrhiza (Danshen). In one study,
treatment with salvianic acid A inhibited proliferation of
HSCs and thus reduced the expression of TGF-β1 and
collagen I/III. Decreased TGF-β1 levels led to inhibition
of plasminogen activator, upregulation of the urokinase-
type plasminogen activator, and dephosphorylation of
Akt and ERK1/2 [62].
Betulin and its oxidized form betulinic acid (Figure 3),
a type of triterpene derived from the bark of Betula pla-
typhylla var. japonica, can reverse alcohol-induced cyto-
toxicity in HepG2 cells [63]. Treatment with betulin and
betulinic acid inhibited expression of TNF-α, TGF-β1,Salvianic acid A  
Betulinic acid  
ctivity, including genistein, salvianic acid A, botulin, and betulinic acid.
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and activated matrix metalloproteinase (MMP)-2 in
alcohol-induced liver fibrosis in vivo [64].
The Chinese herbal formula, Gexia Zhuyu decoction
(Gexia Zhuyu Tang; GZT), can attenuate fibrosis and re-
duce inflammation in the late stage of liver fibrosis [65].
Treatment with GZT improved degeneration and in-
flammatory necrosis in liver cells, and reduced CCl4-
induced collagen deposition in vivo [66].
Cytokine inhibitors attenuate hepatic fibrogenesis
Research shows that suppression of insulin-like growth
factor I improves liver function and reduces liver fibrosis
through upregulation of MMPs and downregulation of
TIMPs [67]. Elevated levels of IL-17 and its receptors in
response to liver damage may also promote the produc-
tion of IL-1, IL-6, TGF-α, and collagen I that promote
liver fibrosis. Treatment of these kinds of cytokine inhib-
itors could contribute to inflammation accumulation in
the fibrotic liver [68]. The cytokine inhibitors can also
decrease IL-22 expression-induced HSC senescence and
inhibit hepatic fibrogenesis [69].
The herbal formula Yanggan Wan (YGW) has been
shown to be hepatoprotective [70], deactivating HSCs
through epigenetic de-repression of PPAR-γ in common
bile duct-induced cholestatic liver fibrosis mice [71]. The
de-repressed PPAR-γ was induced by reduced MeCP2
expression and its recruitment to the PPAR-γ promoter
[71]. Rosmarinic acid and baicalin (Figure 4) from YGW
de-repressed PPAR-γ through suppression of canonical
Wnt signaling in activated HSCs [71]. Baicalin shifts the
balance of profibrotic to antifibrotic cytokines and reduces
oxidative stress in the fibrotic liver in experimental animalRosmarinic acid 
Oleanolic acid Ursolic acid 
Figure 4 Cytokine inhibitors, including ursolic acid, paeniflorin, baicalin, an
acid, ursolic acid, and obeticholic acid as nuclear receptor modulators.models [72], while romarinic acid can also inhibit prolifer-
ation and induce apoptosis of HSCs [73].
Treatment with Yin Chen Hao decoction (Yin Chen
Hao Tang; YCHT) can decrease serum IFN-γ and IL-12
levels [74]. In the DMN-induced liver fibrotic rat, treat-
ment with YCHT significantly improved the pathological
condition through inhibition of α-SMA activation and
transcription of its target genes [75].
Paeoniflorin (Figure 4), the major bioactive constituent
of Moutan cortex (Mudanpi), effectively attenuated
CCl4-induced liver fibrosis [76]. In one study, treatment
with paeoniflorin reduced the size of egg granuloma, fi-
brosis scores, IL-13 serum concentration, and hydroxy-
proline content in the liver of mice infected with S.
japonicum. Paeoniflorin also showed an inhibitory effect
on hepatic fibrogenesis through downregulation of IL-13
expression and abrogation of the IL-13 signaling path-
way in activated HSCs [77].
Nuclear receptors that modulate liver fibrogenesis
FXR is highly expressed in activated HSCs in the fibrotic
liver [78]. FXR ligands prevent hepatic fibrogenesis
through deactivation of HSCs and decreased ECM ex-
pression [78].
Oleanolic acid and ursolic acid (Figure 4) are triter-
penoid saponins commonly identified in medicinal
plants [79]. Treatment with oleanolic acid inhibited the
production of bile acids through blocking the interac-
tions between FXR and its coactivator SRC-3 and en-
dogenous ligand chenodeoxycholic acid [80]. Oleanolic
acid blocked the binding of endogenous ligand cheno-
deoxycholic acid to FXR, suppressing expression of
FXR-targeted bile salt export protein. There is evidencePaeoniflorin Baicalin 
Obeticholic acid 
d rosmarinic acid, and nuclear receptor modulators, including oleanolic
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radical content through increasing hepatic transcription
of Nrf2 target genes, including NAD(P)H:quinone oxido-
reductase 1, glutamate-cysteine ligase, catalytic subunit,
heme oxygenase-1, and Nrf2 itself [81,82].
Antioxidants as hepatoprotective agents in liver fibrosis
management
Silymarin, the extract of the milk thistle or Silybum mar-
ianum (Shuifeiji), consists of four flavonolignan isomers:
silybin, isosilybin, silydianin, and silychristin (Figure 5).
Silymarin has been widely used as a single-herb remedy
for treating liver diseases. Silymarin treatment protects
further liver damage by its antioxidant and anti-
inflammatory activities [83,84]. Silybinin, also called sily-
bin, exhibited hepatoprotective and antifibrogenic effects
by inhibiting TGF-β1-induced collagen secretion and
oxidase stress both in vivo and in vitro [85].
Acanthus ilicifolius alkaloid A (4-hydroxy-2(3H)ben-
zoxazolone) was first isolated from Acanthus ilicifolius
(Juechuangle) [86]. Acanthus ilicifolius alkaloid A and its
acyl derivatives have been used as antioxidant, anti-
inflammatory, and analgesic agents [87]. This group of an-
alogs inhibits progression of CCl4-induced liver fibrosis by
reducing lipid peroxidation and oxidative stress [88].
Curcumin (Figure 5), the main active component of
turmeric, protects the CCl4-induced fibrotic liver
through its antioxidant activity [89,90]. Treatment with
curcumin suppressed multiple pro-angiogenic factors
that modulate cannabinoid receptors and inhibited ECM
expression, thus decreasing collagen deposition [89,91].
In one study, treatment with curcumin also increasedC
Silybin Isos
Silychristin 
Figure 5 Chemical structures of antioxidative agents, including silybin, isosserum MMP-13 and glutathione levels, thus reversing fi-
brosis in CCl4-induced liver fibrosis in rats [91].
β-caryophyllene (Figure 5) is a natural sesquiterpene
identified in the essential oil of numerous plants and
fruits [92]. In one study, β-caryophyllene exhibited high
scavenging activity against hydroxyl radicals and super-
oxide anions, which inhibited lipid peroxidation and
suppressed expression of Col1a1 and TIMP-1 in CCl4-
induced mouse liver fibrosis [93].
Modulation of the balance between EMT and MET to
treat liver fibrosis
Treatment with Diwu Yanggan (DWYG) significantly de-
creased the hepatic hydroxyproline content and degree
of CCl4-induced liver fibrosis in rats [94] and stimulated
MET in the fibrotic liver through inhibition of the TGF-
β1/BMP-7 signaling pathway [94].
Research shows that Fuzheng Huayu (FZHY) formula
reverses EMT in the fibrotic kidney through suppression
of α-SMA, TGF-β1, and nuclear translocation of SMAD3
[95]. In one study using the renal fibrosis model, treatment
with salvianolic acid B from Danshen abrogated EMT by
counteracting the TGF-β1 signaling pathway [96].
Herbal medicines and natural products in clinical trials
FZHY formula to treat liver fibrosis [97] has completed
phase II clinical trials approved by the FDA [98,99].
FZHY tablet consists of R. miltiorrhizae (Danshen), fer-
mented Mycelium (Chongcao), Semen persicae (Taoren),
Fructus schisandrae (Wuweizi), Chinensis pollen pini
(Songhuafen), and Gynostemma pentaphyllammak
(Jiaogulan) [100]. Administration of FZHY tableturcumin -Caryophyllene 
ilybin Silydianin 
ilybin, silydianin, silychristin, curucmin, and β-caryophyllene.
Chen et al. Chinese Medicine  (2015) 10:7 Page 10 of 13improved liver function, serum fibrotic parameters and
cirrhosis; decreased portal pressure; and regulated im-
mune function and amino acid balance in 216 liver fi-
brosis patients with chronic HBV in a multicenter
study [98]. Patients with posthepatitic cirrhosis showed
improved liver function, decreased fibrotic score, pro-
longed 2-year survival, and reduced symptom scores
after administration of FZHY tablet [101]. A multicen-
ter, double-blind, randomized, and controlled clinical
trial confirmed the efficacy of FZHY tablet, which de-
creased serum hyaluronic acid levels in patients with
chronic HBV caused by cirrhosis [102]. Supplemental
administration of FZHY tablet with nucleos(t)ide ana-
logs to patients with chronic HBV also decreased serum
fibrosis markers, including hyaluronic acid, laminin,
amino-terminal propeptide of type III procollagen, and
IV collagen [103].
FZHY tablet exhibits multiple mechanisms of action
against liver fibrosis/cirrhosis [101]; its known active
ingredients include salvianoic acid B and adenosine
[102]. FZHY tablet exhibits antifibrotic activity by indu-
cing apoptosis in HSC-T6 cells through p38 and SAPK/
JNK pathways [99,104], and inhibits liver fibrosis
through decreasing transcription of TIMP-1, PDGF-B,
and PDGF receptor β1 in vivo [99]. A study of chronic
HBV infection-induced fibrosis and cirrhosis patients
showed that its therapeutic efficacy is closely related to
the GA plus AA polymorphism of CYP1A2 [105].
Fufang Biejia Ruangan (FFBJRG) pill, consisting of Car-
apax Trionycis (Biejia), Radix Paeoniae Rubra (Chishao),
Radix Angelicae Sinensis (Danggui), Codonopsis Pilosula
(Dangshen), and Radix Astragali (Huangqi), is the first
anti-liver fibrosis drug approved by the China Food and
Drug Administration [106]. FFBJRG pill inhibited hep-
atic fibrosis in vitro and in vivo by inhibiting TGF-β1/
SMAD pathway transduction [107] and is currently in
phase IV clinical trials in the United States for theObeticholic acid 
Figure 6 Chemical structures of oleanolic acid, and docosahexaenoic acid.treatment of chronic HBV infection-associated liver fi-
brosis [108].
Treatment with silybin-phospholipids and vitamin E
complex (SPV complex) significantly reduced liver
fibrosis scores and downregulated fibrosis markers in
fatty liver-associated HCV-positive patients in 11 Italian
and 2 Romanian centers [109]. The SPV complex is
currently in phase III clinical trials in the US for the
treatment of liver fibrosis. The anti-liver fibrosis effect
of the SPV complex is mainly due to deactivation of
HSCs and downregulation of TGF-β1 and TNF-α
expression [110].
Obeticholic acid (Figure 6) is a semisynthetic deriva-
tive of bile acid and an FXR agonist. Treatment with
obeticholic acid inhibits synthesis and accumulation of
bile acid in the liver [111]. Patients with type 2 diabetes
and non-alcoholic fatty liver disease showed significantly
reduced markers of liver inflammation and fibrosis after
administration of 25 mg obeticholic acid for 6 weeks in
a phase II clinical trial in the US [112].
Docosahexaenoic acid (DHA, Figure 6), an omega-3
fatty acid, was originally isolated from maternal milk or
fish oil. DHA is in phase II clinical trials for the treat-
ment of liver fibrosis in the US [113]. Treatment with
DHA inhibited hepatic fibrogenesis through suppression
of Procol1α1 and TGF-β1 and inhibited hepatic inflam-
mation and oxidative stress markers, including TLR4,
TLR9, CD14, MyD88, and different NADPH oxidase
subunits [114].
Conclusion
Despite cumulative evidence of success in treating liver
fibrosis, in vivo results are insufficient to confirm the
clinical efficacy of natural products and herbal medicines
for liver fibrosis. The identification of resources and the
molecular mechanisms of action of these substances re-
main extremely challenging.Docosahexaenoic acid 
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